Marshall Wace’s Bicara Therapeutics BCAX Stock Holding History

Marshall Wace’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-112,086	Closed	-$1.77M	–	3606
2025 Q3	$1.77M	Buy	112,086 +60,277	+116%	+$675K	﹤0.01%	1676
2025 Q2	$481K	Buy	+51,809	New	+$617K	﹤0.01%	2163
2025 Q1	–	Sell	-67,733	Closed	-$1.18M	–	3179
2024 Q4	$1.18M	Buy	+67,733	New	+$1.41M	﹤0.01%	1660

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RTM

Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $173M AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Marshall Wace's BCAX Position: Q4 2025 in Review

Marshall Wace sold out of Bicara Therapeutics (BCAX) in Q4 2025, closing a stake of 112,086 shares — an estimated $1.77M sold.

Marshall Wace first reported a position in BCAX in Q4 2024 and held it in 3 quarters. The position peaked at $1.77M in Q3 2025. 141 funds tracked by Wall St. Rank hold BCAX as of Q4 2025.

Marshall Wace reported no remaining Bicara Therapeutics position as of Q4 2025 after selling out during the quarter.
Marshall Wace sold 112,086 Bicara Therapeutics shares in Q4 2025, an estimated $1.77M.
Marshall Wace first reported a position in Bicara Therapeutics in Q4 2024 and held it in 3 quarters.
Marshall Wace's Bicara Therapeutics position peaked at $1.77M in Q3 2025.
141 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.